Table 2. Characteristics of 30 MDR TB and XDR TB patients, South Africa*.
| Characteristic | MDR TB | 6- or 7-drug XDR TB | 8-drug XDR TB |
|---|---|---|---|
| Total | 11 | 6 | 13 |
| Female sex | 8 (73) | 4 (67) | 5 (38) |
| Age, y, median (range) |
36 (26–52) |
42.5 (36–64) |
33.5 (24–51) |
| Prior TB treatment | |||
| First-line drugs† | 5 (45) | 5 (83) | 5 (38) |
| Second-line drugs‡ |
0 |
0 |
0 |
| TB contact | 2 (18) | 2 (33) | 1 (8) |
| Enrollment site at HIV clinic | 8 (73) | 2 (33) | 7 (54) |
| HIV positive | 10 (91) | 5 (83) | 12 (92) |
| CD4 cell count, cells/mm3, median (range) | 155 (25–708) | 117.5 (18–426) | 183.5 (22–670) |
| Receiving antiretroviral therapy (among HIV-positive patients) | 7 (70) | 2 (40) | 2 (17) |
*Values are no. (%) unless otherwise indicated. MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant TB. 6-drug resistance, resistance to isoniazid, rifampin, ethambutol, ofloxacin, kanamycin, and streptomycin; 7-drug resistance, resistance to isoniazid, rifampin, ethambutol, ofloxacin, kanamycin, streptomycin, and capreomycin; 8-drug resistance, resistance to isoniazid, rifampin, ethambutol, ofloxacin, kanamycin, streptomycin, capreomycin, and ethionamide. †First-line drugs used for treatment of persons with new TB cases or confirmed drug-susceptible TB include isoniazid, rifampin, ethambutol, and pyrazinamide. ‡Second-line drugs used for treatment of persons with confirmed MDR TB include ofloxacin, kanaymycin, ethionamide, p-aminosalicylic acid, and cycloserine or terizidone.